Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426675 | 1.00 | ADORA2A (0.76) | ADORA2AADORA1ADORA3 | |
| SCHEMBL14415212 | 0.87 | ADORA2A (0.76) | ADORA2AADORA1ADORA3 | |
| SCHEMBL12217748 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL12629177 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL1858701 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL24436871 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL24436981 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL1864206 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL22452094 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 | |
| SCHEMBL1860498 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-8895530-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA2A 25/4885ADORA1 18/4885ADORA3 31/4885 |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA2A 25/4885ADORA1 18/4885ADORA3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.